Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-2325a
- Development stage
- Phase 1
- Lead developer
- Daiichi Sankyo
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Gene Therapies
- Administration
- Subcutaneous
01
Overview
DS-2325a is an investigational gene therapy developed by Daiichi Sankyo for the treatment of Netherton Syndrome, a rare genetic skin disorder characterized by generalized scaling, erythema, and epidermal barrier defects. DS-2325a is a fusion protein composed of genetically engineered human serine peptidase inhibitor KAZAL Type 2 (SPINK2) fused to the Fc region of human immunoglobulin G1. It acts as a specific and potent inhibitor of kallikrein 5 (KLK5), an enzyme believed to be overactive in Netherton Syndrome. By inhibiting KLK5 activity, DS-2325a aims to improve symptoms associated with the disease. The drug is currently in Phase 1/2 clinical trials for Netherton Syndrome[1][3][4][6].
- Other names
- a fusion protein comprised of genetically engineered human serine peptidase inhibitor KAZAL Type 2 (SPINK2) and human immunoglobulin G (IgG) 1 Fc
02
Targets
KLK5 (Kallikrein-related peptidase 5)
Beyond the preview
Go deeper on DS-2325a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-2325a.